乳腺癌组织标志物、基因组图谱及其他预后因素:放射科医师入门
本文面向放射科医师,系统回顾乳腺癌预后因素,涵盖患者因素(年龄、种族与民族、生活方式)、影像表现(多中心/多灶病变、广泛导管内成分、皮肤或胸壁受累)、组织病理(分级、淋巴血管侵犯)及肿瘤生物标志物与分子分型(Luminal A、Luminal B、HER2富集型、三阴性);了解这些因素的临床影响有助于放射科医师与多学科团队合作实现个体化诊疗。
要点
- 肿瘤大小和淋巴结状态是已确立的独立不良预后因素,已纳入AJCC TNM分期系统。
- 影像上多中心/多灶病变、广泛导管内成分、皮肤或胸壁受累影响治疗决策与预后。
- 组织学分级和淋巴血管侵犯是重要的组织病理预后因素。
核心结论
- 理解上述预后因素的临床影响,放射科医师可与多学科团队协作,利用这些工具实现个体化患者诊疗并改善患者结局。
研究设计与样本
- 综述(Radiographics 2018),围绕患者因素、影像表现、组织病理和肿瘤生物标志物与生物学四部分展开;原文未报告检索范围与纳入文献数量。
关键影像表现/征象
- 影像上多中心/多灶病变、广泛导管内成分及皮肤或胸壁受累影响治疗与预后。
- 肿瘤大小和淋巴结状态是已确立的独立不良预后因素。
- 组织病理方面,分级和淋巴血管侵犯为相关预后因素。
- 分子分型包括Luminal A、Luminal B、HER2富集型和三阴性四类。
诊断标准与关键数值
- 美国癌症联合委员会(AJCC)TNM分期系统纳入肿瘤大小和淋巴结状态作为独立预后因素。
- 美国食品药品监督管理局(FDA)批准多个肿瘤基因表达微阵列检测 panel,并获得美国临床肿瘤学会(ASCO)认可。
- 肿瘤按分子特征分为Luminal A、Luminal B、HER2富集型和三阴性四种亚型。
- 预后评估涉及激素受体、增殖标志物等肿瘤生物标志物。
临床应用与阅片要点
- 放射科医师阅片时应关注多中心/多灶病变、广泛导管内成分以及皮肤或胸壁受累,这些影像表现与治疗和预后相关。
- 放射科医师了解组织标志物、基因组图谱及其他预后因素,有助于与多学科团队协作实现个体化患者诊疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
An understanding of prognostic factors in breast cancer is imperative for guiding patient care. Increased tumor size and more advanced nodal status are established independent prognostic factors of poor outcomes and are incorporated into the American Joint Committee on Cancer (AJCC) TNM (primary tumor, regional lymph node, distant metastasis) staging system. However, other factors including imaging findings, histologic evaluation results, and molecular findings can have a direct effect on a patient's prognosis, including risk of recurrence and relative survival. Several microarray panels for gene profiling of tumors are approved by the U.S. Food and Drug Administration and endorsed by the American Society of Clinical Oncology. This article highlights prognostic factors currently in use for individualizing and guiding breast cancer therapy and is divided into four sections. The first section addresses patient considerations, in which modifiable and nonmodifiable prognostic factors including age, race and ethnicity, and lifestyle factors are discussed. The second part is focused on imaging considerations such as multicentric and/or multifocal disease, an extensive intraductal component, and skin or chest wall involvement and their effect on treatment and prognosis. The third section is about histopathologic findings such as the grade and presence of lymphovascular invasion. Last, tumor biomarkers and tumor biology are discussed, namely hormone receptors, proliferative markers, and categorization of tumors into four recognized molecular subtypes including luminal A, luminal B, human epidermal growth factor receptor 2-enriched, and triple-negative tumors. By understanding the clinical effect of these prognostic factors, radiologists, along with a multidisciplinary team, can use these tools to achieve individualized patient care and to improve patient outcomes. ©RSNA, 2018.
引用
- Tirada N, Aujero M, Khorjekar G, et al. Breast Cancer Tissue Markers, Genomic Profiling, and Other Prognostic Factors: A Primer for Radiologists. Radiographics. 2018. PMID: 30312139. doi:10.1148/rg.2018180047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。